EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Brain Cancer, Brain Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/19/2018 |
| Start Date: | February 2004 |
| End Date: | July 2009 |
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
The purpose of this study is to determine the safety of the drug EPO906 that could shrink
tumors when used with radiation therapy in cancer patients.
tumors when used with radiation therapy in cancer patients.
- To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with
radiation therapy and establish a recommend phase II dose.
- To evaluate the safety and toxicity profile of EPO906 when administered concurrently
with radiotherapy in three disease cohorts.
- To evaluate tumor response.
radiation therapy and establish a recommend phase II dose.
- To evaluate the safety and toxicity profile of EPO906 when administered concurrently
with radiotherapy in three disease cohorts.
- To evaluate tumor response.
Inclusion Criteria:
- Requires a minimum of 3 weeks of radiation therapy
- Solid tumors with advanced or recurrent disease for which there is no standard therapy
or tumors have failed standard therapy
- World Health Organization (WHO) performance status equal to or less than 2
- Life expectancy equal to or greater than 3 months
Exclusion Criteria:
- Any peripheral neuropathy
- Unresolved diarrhea greater than grade 1
- Patients who received any other investigational compound within the past 28 days
- Severe cardiac insufficiency
- Patients on Coumadin
We found this trial at
1
site
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
Click here to add this to my saved trials
